The story of Sildenafil presents a interesting case for stakeholders in the drug sector. While initially a tremendous success, producing huge profits, the patent expiration and the subsequent entry of off-brand versions have significantly impacted earnings. This poses questions about the future sustainability of related medication developments a… Read More